NCT06565546
CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria shortened, about 22 words
- Trial completed
- Final enrollment: 57 participants (planned 100)
- Primary completion date changed from estimate of Sep 1, 2026 to Oct 31, 2026
- Minor Primary completion pushed from Jun 1, 2026 to Sep 1, 2026
- Study completion pushed from Jul 2026 to Oct 2026
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date: Dec 2025 to Jun 1, 2026
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jan 2025 to Jan 29, 2025
- Notable Start date: Sep 2024 to Jan 2025
- Primary completion date: Jul 2025 to Dec 2025
- Study completion date: Dec 2025 to Jul 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
CYP2D6 genotype testing performed preoperatively with results used to guide prescribing of opioid analgesics during the postoperative period to control pain. In addition, participants will receive standard of care postoperative pain medications.
CYP2D6 genotype testing performed preoperatively, results will be delayed until after operative procedure. Participants will receive standard of care postoperative pain medication prescriptions for pain management.
Other: Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin, Acetaminophen and Gabapentin: standard postoperative pain medications
Sites
1 site in 1 country
- University of Florida JacksonvilleJacksonville, Florida, United States